^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lutetium zadavotide guraxetan (PNT2002)

    i
    Other names: PNT2002, 177Lu-PSMA-I&T, 177Lu-PNT2002, PNT-2002, PNT 2002
    Company:
    Eli Lilly, Lantheus
    Drug class:
    Beta radiation emitter, PSMA inhibitor
    Related drugs:
    9d
    VALOR: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial primary completion date
    |
    Zolinza (vorinostat) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • lutetium zadavotide guraxetan (PNT2002)
    15d
    VALOR: Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=15, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    Zolinza (vorinostat) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • lutetium zadavotide guraxetan (PNT2002)
    15d
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=1, Terminated, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=10 --> 1 | Trial completion date: Feb 2035 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Mar 2030 --> Nov 2025; Sponsor is no longer producing the study drug, so it was not possible to complete the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    lutetium zadavotide guraxetan (PNT2002)
    2ms
    PSMA-PRED: Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Centre Jean Perrin | Trial completion date: Dec 2028 --> Jun 2034 | Trial primary completion date: Dec 2026 --> Jun 2034
    Trial completion date • Trial primary completion date
    |
    lutetium zadavotide guraxetan (PNT2002)
    6ms
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N=37 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Keytruda (pembrolizumab) • lutetium zadavotide guraxetan (PNT2002)
    7ms
    Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=48, Suspended, Weill Medical College of Cornell University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    CELLSEARCH®
    |
    lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    10ms
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lutetium zadavotide guraxetan (PNT2002)
    1year
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2035 --> Feb 2035 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Dec 2030 --> Mar 2030
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    lutetium zadavotide guraxetan (PNT2002)
    1year
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2031 --> Jan 2032 | Initiation date: Nov 2024 --> May 2025 | Trial primary completion date: Jul 2030 --> Jan 2031
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • lutetium zadavotide guraxetan (PNT2002)
    over1year
    177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=10, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Sep 2024 --> Dec 2024
    Trial initiation date
    |
    lutetium zadavotide guraxetan (PNT2002)
    over1year
    177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (clinicaltrials.gov)
    P2, N=93, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Sep 2025 --> Sep 2033 | Trial primary completion date: Sep 2024 --> Sep 2032
    Trial completion date • Trial primary completion date
    |
    lutetium zadavotide guraxetan (PNT2002)
    over1year
    PSMA Therapy and Immunotherapy in Kidney Cancer (clinicaltrials.gov)
    P1/2, N=37, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Initiation date: Jul 2024 --> Nov 2024
    Trial initiation date • Metastases
    |
    Keytruda (pembrolizumab) • lutetium zadavotide guraxetan (PNT2002)